• OPEN AN ACCOUNT
Indian Indices
Nifty
24,666.90 88.55
(0.36%)
Sensex
81,330.56 182.34
( 0.22%)
Bank Nifty
54,801.30 -139.55
( -0.25%)
Nifty IT
37,853.55 498.95
( 1.34%)
Global Indices
Nasdaq
42,160.14 -270.96
(-0.64%)
Dow Jones
5,907.19 42.00
(0.72%)
Hang Seng
38,121.59 -61.67
(-0.16%)
Nikkei 225
8,585.01 -17.91
(-0.21%)
Forex
USD-INR
84.87 -0.55
(-0.64%)
EUR-INR
94.53 -1.49
(-1.55%)
GBP-INR
112.13 -1.43
(-1.26%)
JPY-INR
0.58 -0.01
(-2.04%)

EQUITY - MARKET SCREENER

Ashirwad Steels & Industries Ltd
Industry :  Finance & Investments
BSE Code
ISIN Demat
Book Value()
526847
INE338C01012
65.65936
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
16
39.6
EPS(TTM)
Face Value()
Div & Yield %
1.98
10
0
 

Piramal Pharma gains after receiving EIR for Turbhe facility from USFDA
May 12,2025
According to the company’s exchange filing, the US FDA conducted a general Good Manufacturing Practices (GMP) inspection at the Turbhe facility from 11 February to 17 February 2025. Following the inspection, the US FDA has issued an EIR with a classification of voluntary action indicated (VAI). The receipt of the EIR signifies the successful closure of the inspection.

Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products.

The pharmaceutical company’s consolidated net profit tumbled 63.6% to Rs 3.68 crore despite a 12.54% increase in revenue from operations to Rs 2,204.22 crore in Q3 FY25 over Q3 FY24.